US life sciences company Bruker has acquired the DISQVER platform and selected assets of insolvent German diagnostics startup Noscendo through a restructuring sale. Financial terms were not disclosed. Duisburg-based Noscendo, founded in 2016, developed a method for identifying pathogens in under 24 hours using next-generation sequencing from cell-free DNA. The technology is used by university hospitals for sepsis diagnostics. Despite raising nearly €40 million in venture capital, commercialisation proceeded slower than expected due to delays in selective contracts and economic pressure on hospitals. A planned financing round with existing investors failed in February 2026, leading to insolvency proceedings in March. Insolvency administrator Sarah Wolf from Anchor Rechtsanwälte said the restructuring preserved the technology's value for creditors and partners. Bruker acquired the patent-protected software, intellectual property rights, and select IT and sales staff in Duisburg. The laboratory in Kusterdingen was partially closed in April.